EGFR or HER2 inhibition modulates the tumor microenvironment by suppression of PD-L1 and cytokines release
Koung Jin Suh(Seoul National University Bundang Hospital), Jong Seok Lee(Seoul National University Bundang Hospital)
Cited by 46
Related Papers
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
|The Lancet Oncology|2020|413
Assessment of lymph node metastases using 18F-FDG PET in patients with advanced gastric cancer
|European Journal of Nuclear Medicine and Molecular Imaging|2005|175